J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group

In what appears to be the most expansive policy to date on release of clinical trial data, J&J will use an existing outside group and will share full clinical study reports and patient-level data regardless of when the studies were conducted.

Johnson & Johnson is joining the ranks of companies providing access to its clinical trial data. But it is taking a different approach to the process, leaving it to a group at Yale School of Medicine to review and make final decisions on requests from investigators and physicians for access to anonymized data.

J&J announced on Jan. 30 that it has entered into an agreement with Yale School of Medicine’s Open Data Access...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D